Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
Total Valuation
Adverum Biotechnologies has a market cap or net worth of $91.84M. The enterprise value is $169.28M.
Market Cap$91.84M
Enterprise Value$169.28M
Share Statistics
Adverum Biotechnologies has 22,077,467 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,077,467
Owned by Insiders15.42%
Owned by Institutions30.40%
Financial Efficiency
Adverum Biotechnologies’s return on equity (ROE) is -1.85 and return on invested capital (ROIC) is -94.19%.
Return on Equity (ROE)-1.85
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-94.19%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee6.45K
Profits Per Employee-844.69K
Employee Count155
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Adverum Biotechnologies is ―. Adverum Biotechnologies’s PEG ratio is -0.00310.
PE Ratio―
PS Ratio92.38
PB Ratio1.31
Price to Fair Value1.31
Price to FCF-0.99
Price to Operating Cash Flow-0.72
PEG Ratio-0.00310
Income Statement
In the last 12 months, Adverum Biotechnologies had revenue of 1.00M and earned -130.93M in profits. Earnings per share was -6.62.
Revenue1.00M
Gross Profit1.00M
Operating Income-139.16M
Pretax Income-130.93M
Net Income-130.93M
EBITDA-135.51M
Earnings Per Share (EPS)-6.62
Cash Flow
In the last 12 months, operating cash flow was -137.90M and capital expenditures -543.00K, giving a free cash flow of -138.44M billion.
Operating Cash Flow-137.90M
Free Cash Flow-138.44M
Free Cash Flow per Share-6.27
Dividends & Yields
Adverum Biotechnologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change-37.35%
50-Day Moving Average4.37
200-Day Moving Average3.47
Relative Strength Index (RSI)45.59
Average Volume (3m)794.40K
Important Dates
Adverum Biotechnologies upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Adverum Biotechnologies as a current ratio of 5.73, with Debt / Equity ratio of -159.81%
Current Ratio5.73
Quick Ratio5.73
Debt to Market Cap0.00
Net Debt to EBITDA-0.24
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Adverum Biotechnologies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Adverum Biotechnologies EV to EBITDA ratio is -0.97, with an EV/FCF ratio of -1.33.
EV to Sales123.43
EV to EBITDA-0.97
EV to Free Cash Flow-1.33
EV to Operating Cash Flow-1.33
Balance Sheet
Adverum Biotechnologies has $26.06M in cash and marketable securities with $88.94M in debt, giving a net cash position of -$62.88M billion.
Cash & Marketable Securities$26.06M
Total Debt$88.94M
Net Cash-$62.88M
Net Cash Per Share-$2.85
Tangible Book Value Per Share$3.57
Margins
Gross margin is 0.00%, with operating margin of -15315.90%, and net profit margin of -13092.70%.
Gross Margin0.00%
Operating Margin-15315.90%
Pretax Margin-13092.70%
Net Profit Margin-13092.70%
EBITDA Margin-12727.40%
EBIT Margin-13092.70%
Analyst Forecast
The average price target for Adverum Biotechnologies is $4.90, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.90
Price Target Upside17.79% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast-42.12%